Genalyte rapid COVID-19 antibody test obtains EUA

written by CAP TODAY
December 17, 2020

December 2020—Genalyte announced that its SARS-CoV-2 Multi-Antigen Serology Panel received emergency use authorization from the FDA. The panel tests for IgM and IgG antibodies against 13 unique viral antigens and runs on the company's Maverick diagnostic system, which provides results in 20 minutes. The test demonstrated 98 percent specificity and 96 percent sensitivity.

Genalyte, 858-956-1200